Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
$0.25
-$0.17(-7.61%)
At close: 4:00 PM EST
$0.25
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.16 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)2.51M
Market Cap
$26.16M
Enterprise Value$38.50M
Total Cash (Recent Filing)$8.68M
Total Debt (Recent Filing)$36.89M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 14, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding104,614,220
10 Day Avg. Volume4,953,759
30 Day Avg. Volume2,511,307
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue187.34
Enterprise Value/Gross Profit-31.82
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$3.25Price Target Upside1200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$21.21M
Bulls Say, Bears Say
Bulls Say
Analyst OutlookAnalyst's recommendation remains a buy because FDA approval and successful commercialization are viewed as likely upside events that are not reflected in the current share price.
European CommercializationCommercial launches of Lytenava have begun in certain European markets with initial rollout progressing and further country launches planned, offering early revenue opportunities and broader market exposure.
Study AcknowledgmentRegulatory agency acknowledged an earlier study as adequate and well controlled, which could support future submissions if paired with compelling confirmatory evidence.
Bears Say
FDA ObjectionsFDA issued Complete Response Letters citing manufacturing and chemistry concerns and indicated that additional mechanistic and natural history data did not change its conclusion, making confirmatory clinical evidence a prerequisite for approval.
Liquidity RiskBalance sheet shows limited cash relative to debt, creating a constrained cash runway and increasing the likelihood that additional financing will be required.
Trial Outcome ConcernsA pivotal study failed to meet its pre-specified primary endpoint and the company relied on a non-pre-specified analysis in its resubmission, weakening confidence in the existing efficacy dataset.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $26.16M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is May 14, 2026 which is in 35 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Feb 17, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.227 by $0.007.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 104,614,220 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.227. Following the earnings report the stock price went down -13.878%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$3.25
▲(1200.00% Upside)
Technical Analysis
Ownership Overview
16.99% Insiders
1.93% Mutual Funds
2.11% Other Institutional Investors
77.37% Public Companies and Individual Investors